Two years into an R&D overhaul, GSK plans $250M lab project near Philly for another migration of US staffers
GlaxoSmithKline set out to completely overhaul its US R&D organization in late 2014, axing hundreds of staffers in its longtime drug investigation center in Research Triangle Park to counter the sluggish progress of its pipeline. The move by CEO Andrew Witty set in motion a series of restructuring waves that have had a profound impact on its research groups, now centered in Philadelphia and Stevenage in the UK.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.